Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
For more information on Nouscom, please visit the company’s website at www.nouscom.com
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
For more information on Nouscom, please visit the company’s website at www.nouscom.com
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $135.77M
Investors 5
| Date | Name | Website |
| - | Panakes Pa... | panakes.it |
| - | 5AM Ventur... | 5amventure... |
| - | Andera Par... | anderapart... |
| - | Abingworth... | abingworth... |
| - | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.11.2023 | Series C | $73.43M | - |
| 06.11.2017 | Series B | $48.77M | 5AM Ventur... |
| 17.05.2016 | Series A | $13.57M | - |
Mentions in press and media 39
| Date | Title | Description |
| 30.10.2025 | Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting | The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the c... |
| 13.10.2025 | Clinical milestones bring startups closer to launching new therapies | Following a positive meeting with the U.S. Food and Drug Administration (FDA), Oculis is advancing Privosegtor, a new peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis ... |
| 09.05.2025 | Milestones achievements for life sciences startups | Nouscom, a clinical-stage biotech company developing next-generation neoantigen-targeted off-the-shelf and personalized cancer immunotherapies, has presented the safety and immunogenicity results from a Phase Ib/II study evaluating NOUS-20... |
| 13.12.2024 | The Dawn of Drone Dominance: Auterion and Rheinmetall's Game-Changing Alliance | In the world of defense technology, the skies are no longer the limit. They are the battlefield. Auterion, a leader in drone operating systems, has teamed up with Rheinmetall, a titan in defense technology. Together, they are crafting a new... |
| 11.12.2024 | New leaders with a fresh perspective for several startups | Pure Holding, a renowned Swiss cannabis company focusing on research, production, processing & distribution has welcomed Janna Eisenbrandt has joined the leadership team as the new CFO. Janna brings with her a wealth of experience in s... |
| 25.11.2024 | POWHER Awards für drei Unternehmerinnen | Der gemeinnützige Verein «Female Entrepreneurs Basel» hat zum dritten Mal die POWHER Awards in drei Kategorien vergeben. Damit werden Frauen ausgezeichnet, die durch innovatives Handeln und unternehmerisches Engagement Erfolge erzielt habe... |
| 06.11.2024 | Biotech companies report progress in clinical trials | Following the sale of its lead molecule NM26 to Johnson & Johnson for USD 1.25 billion in May, Numab Therapeutics announced the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific immuno-oncology therapeut... |
| 27.07.2024 | The Future of Diagnostics: Roche's Vision Unveiled at ADLM 2024 | In the bustling heart of Chicago, Roche is setting the stage for the future of laboratory diagnostics. At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo, the company is showcasing a suite of innovati... |
| 23.07.2024 | Erfahrene Expertinnen und Experten verstärken Startup-Management | Das EHT-Spin-off Riverkin begrüsst mit Nitin Kumar and Marco Adriano Magno zwei neue Mitgründer. Nitin Kumar hat einen Doktortitel in Computational Biology und war an einigen erfolgreichen Startup-Exits beteiligt. Mit diesen Erfahrungen kö... |
| 26.03.2024 | Nouscom secures additional funding from Angelini Ventures | Based in Basel, Nouscom is a clinical stage immune-oncology company developing off-the-shelf and personalized cancer vaccines based on its proprietary viral vector platform, which has the capacity to encode for large payloads of neoantigen... |
Show more